Oncology Data Advisor is excited to be launching our new podcast series, "Exploring Artificial Intelligence in Oncology." Hosted by Waqas Haque, MD, MPH, Member of the Oncology Data Advisor Fellows Forum, this series will delve into the burgeoning roles and uses of AI in cancer care, from pathology to toxicity risk prediction to treatment recommendations and beyond.

Exploring Artificial Intelligence in Oncology

In this first episode of Oncology Data Advisor’s new podcast series, “Exploring Artificial Intelligence in Cancer Care,” Dr. Waqas Haque and Dr. Matthew Hadfield of the OncData Fellows Forum engage in a discussion with Dr. Ofer Sharon, CEO of OncoHost. Dr. Sharon provides an overview of the clinical need for increased knowledge of patients’ probabilities of developing immune-related adverse events and explains the PROphet® platform, OncoHost’s novel plasma-based, proteomic pattern analysis tool that uses a single blood sample to guide immunotherapy treatment decisions.

Predicting Immune-Related Adverse Events Through Machine Learning With Dr. Ofer Sharon of OncoHost

This second episode of Oncology Data Advisor's podcast series, Exploring Artificial Intelligence in Oncology, features Leif Honda, Chief Innovation Officer at TriMetis, a digital pathology company focused on improving patient outcomes by accelerating human tissue-based research, development, and testing. Dr. Waqas Haque, member of the Oncology Data Advisor Fellows Forum, speaks with Mr. Honda about the TriMetis Computer-Assisted Pathology (TCAP) AI platform, including how it was developed and trained, its capabilities for streamlining the pathology workflow, and the ongoing process of preparing it for clinical utility.

Streamlining the Pathology Workflow Through AI: Waqas Haque and Leif Honda of TriMetis

In this installment of Oncology Data Advisor's Exploring AI in Oncology series, Dr. Waqas Haque speaks with Dr. Shaalan Beg, an Adjunct Associate Professor at the University of Texas (UT) Southwestern, who is spearheading efforts to decentralize clinical trials in oncology and expand access for eligible patients. Dr. Beg describes the tools that are currently in development for decentralizing trials, including the use of artificial intelligence (AI), natural language processing, and telehealth. Additionally, he shares his perspectives on transitioning to a career in industry.

Expanding Clinical Trial Access With Decentralization and Technology: Waqas Haque and Shaalan Beg

In this installment of Oncology Data Advisor's Exploring Artificial Intelligence in Oncology series, Dr. Waqas Haque, Fellows Forum member and incoming Hematology/Oncology Fellow at the University of Chicago, speaks with Tracey Sikora, Co-Founder of Every Cure, a nonprofit organization whose mission is to repurpose existing FDA-approved drugs for other indications, especially in rare diseases. 

Check out the discussion to learn more about: 
•	Challenges in finding treatments for rare diseases, including sparse data, low patient numbers, and lack of financial incentive for pharmaceutical companies
•	Every Cure’s mission to unlock the potential of drugs that are already on the market
•	Harnessing the latest AI and machine learning technology to structure data in a biomedical knowledge graph, looking at drugs, diseases, pathways, and targets
•	Barriers in drug repurposing, including clinical validation and eventual approval
•	The Advanced Research Projects Agency for Health (ARPA-H) grant and the importance of federal funding for rare disease research
•	How to develop efficient clinical trials without a large sample size
•	The future of AI-enabled drug discovery in oncology 
•	And more!

Every Cure: Unlocking Drug Potential With Artificial Intelligence With Waqas Haque and Tracey Sikora

This installment of Oncology Data Advisor's Exploring Artificial Intelligence (AI) in Oncology series features a discussion recorded live at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting between Ranjana Devi, Vice President of Product Development, Oncology, at Qure.ai, and Fellows Forum member Dr. Waqas Haque. 

Check out the episode to hear more about: 
•	Qure.ai’s mission of making healthcare more accessible and equitable to patients worldwide through innovations in deep learning and AI
•	Current challenges in lung cancer screening and the capabilities of AI in addressing these gaps
•	Qure.ai’s end-to-end AI-powered solutions for early lung cancer detection and care
•	The efficacy of these solutions and how they can be used in the clinic
•	The lung cancer portfolio that Qure.ai showcased at ASCO
•	Other innovations coming down the pipeline
•	And more!

Qure.ai: Improving Early Lung Cancer Detection Through AI with Ranjana Devi and Waqas Haque, MD, MPH

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Waqas Haque, a Hematology/Oncology Fellow at the University of Chicago, recently shared his perspectives on i3 Health’s CME activity, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With MCED testing moving from research to real-world practice, Dr. Haque discussed the science, challenges, and future of these innovative tests, as well as the importance of staying up to date on emerging advances with continuing education. 

Click the links below for the full CME activity!

Module 1: https://bit.ly/3X8apxa
Module 2 : https://bit.ly/41rS14I
Module 3: https://bit.ly/4b9JU00


And view the slide decks here:

Module 1: https://bit.ly/4l0NTzc
Module 2: https://bit.ly/4fdXwti
Module 3: https://bit.ly/40AkmoP

Multicancer Early Detection: A Fellow’s Perspective With Waqas Haque, MD, MPH

Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Waqas Haque, a Hematology/Oncology Fellow at the University of Chicago, recently shared his perspectives on i3 Health’s CME activity, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With MCED testing moving from research to real-world practice, Dr. Haque discussed the science, challenges, and future of these innovative tests, as well as the importance of staying up to date on emerging advances with continuing education.

Click the links below for the full CME activity!

Module 1: bit.ly/3X8apxa
Module 2 : bit.ly/41rS14I
Module 3: bit.ly/4b9JU00

And view the slide decks here:

Module 1: bit.ly/4l0NTzc
Module 2: bit.ly/4fdXwti
Module 3: bit.ly/40AkmoP

oin i3 Health for a special live webinar, Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy, being held on Wednesday, July 30 at 5:00 pm ET. In this exclusive event, Dr. Mathew Maurer, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will share his expertise and latest insights in the treatment of hereditary ATTR-CM.

In this interview, Dr. Maurer shares a preview of the topics he is excited to highlight during the webinar, including signs and symptoms to aid in early diagnosis, advances in genetic testing and new diagnostic modalities, novel therapies that are improving outcomes, and the role of interdisciplinary collaboration.

Don’t miss this opportunity to learn from one of the leading voices in hereditary ATTR-CM care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you!

Register Here: bit.ly/3UgV7nF

Unmasking Hereditary ATTR-CM: A Webinar Preview With Mathew Maurer, MD

For patients with ulcerative colitis, newly developed therapies and tailored treatment strategies have allowed for a more personalized approach to achieving disease control and remission. In this special podcast interview, Dr. Benjamin Cohen, Co-Section Head and Clinical Director of Inflammatory Bowel Diseases at the Cleveland Clinic, offers a behind-the-scenes look at i3 Health’s Virtual Escape Room, which follows Shawn, a 32-year-old man living with ulcerative colitis. Dr. Cohen discusses the greatest challenges in diagnosis and treatment, the importance of staying current with novel therapies and biomarkers, and how this engaging, gamified format not only enhances learning but also translates to improved patient outcomes.
Click here to complete the escape room and claim free CME credit!
https://i3Health.com/uc-escape

Solving the Ulcerative Colitis Puzzle: How to Navigate the Treatment Journey

Don’t miss your chance—listen to Module 1 and claim your CME credit by August 19! 

Join Dr. Charles Vega, a distinguished Clinical Professor of Family Medicine at the University of California, Irvine, as he explores the cutting-edge field of multicancer early detection (MCED). In this engaging session, Dr. Vega delves into the scientific foundations of blood-based cancer screening, examining both current limitations and the exciting promise of MCED technologies. Discover how these innovative tests use biomarkers to detect multiple cancers in a single, convenient screening—offering a breakthrough solution to challenges like low awareness and limited access to screening facilities. 

Remember, you have only until August 19 to listen and earn your CME credit!

Click here to claim your credit: bit.ly/3X8apxa
Click here to download the slide deck: bit.ly/4l0NTzc

EXPIRING SOON! Optimizing Cancer Screening With MCED Technologies - Module 1: Science Behind Cancer Screening

Time is running out—listen to Module 2 and claim your CME credit by August 19!

Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In Module 2, Dr. Charles Vega takes you deeper into the cutting-edge world of multicancer early detection (MCED) tests. With nearly 2 million new cancer cases expected in 2024, early detection is more important than ever. Dr. Vega reviews the latest clinical trial data on MCED tests for gynecologic, gastrointestinal, and hematologic cancers, and explores how these advances could revolutionize cancer screening and improve patient outcomes. 

Don’t forget—you must listen and claim your CME credit by August 19!

Click here to claim your credit: bit.ly/41rS14I
Click here to download the slide deck: bit.ly/4fdXwti

EXPIRING SOON! Optimizing Cancer Screening With MCED Technologies - Module 2: Clinical Evidence for MCED Testing

Hurry—listen to Module 3 and claim your CME credit by August 19!

Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In this final module, Dr. Charles Vega, Clinical Professor of Family Medicine at the University of California, Irvine, explores the practical implementation of multicancer early detection (MCED) tests in clinical practice. Gain valuable insights into how these groundbreaking innovations could transform cancer screening and improve patient outcomes. 

Remember, you have only until August 19 to listen and claim your CME credit!

Click here to claim your credit: bit.ly/4b9JU00
Click here to download the slide deck: bit.ly/40AkmoP

EXPIRING SOON! Optimizing Cancer Screening With MCED Technologies - Module 3: Implementing MCED Testing in Clinical Practice Through Case Studies

Don’t miss your chance—listen to Module 1 and claim your CME credit by August 19!

Join Dr. Charles Vega, a distinguished Clinical Professor of Family Medicine at the University of California, Irvine, as he explores the cutting-edge field of multicancer early detection (MCED). In this engaging session, Dr. Vega delves into the scientific foundations of blood-based cancer screening, examining both current limitations and the exciting promise of MCED technologies. Discover how these innovative tests use biomarkers to detect multiple cancers in a single, convenient screening—offering a breakthrough solution to challenges like low awareness and limited access to screening facilities.

Remember, you have only until August 19 to listen and earn your CME credit!

Click here to claim your credit: bit.ly/3X8apxa
Click here to download the slide deck: bit.ly/4l0NTzc

Time is running out—listen to Module 2 and claim your CME credit by August 19!

Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In Module 2, Dr. Charles Vega takes you deeper into the cutting-edge world of multicancer early detection (MCED) tests. With nearly 2 million new cancer cases expected in 2024, early detection is more important than ever. Dr. Vega reviews the latest clinical trial data on MCED tests for gynecologic, gastrointestinal, and hematologic cancers, and explores how these advances could revolutionize cancer screening and improve patient outcomes.

Don’t forget—you must listen and claim your CME credit by August 19!

Click here to claim your credit: bit.ly/41rS14I
Click here to download the slide deck: bit.ly/4fdXwti

Hurry—listen to Module 3 and claim your CME credit by August 19!

Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In this final module, Dr. Charles Vega, Clinical Professor of Family Medicine at the University of California, Irvine, explores the practical implementation of multicancer early detection (MCED) tests in clinical practice. Gain valuable insights into how these groundbreaking innovations could transform cancer screening and improve patient outcomes.

Remember, you have only until August 19 to listen and claim your CME credit!

Click here to claim your credit: bit.ly/4b9JU00
Click here to download the slide deck: bit.ly/40AkmoP

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Expanding Clinical Trial Access With Decentralization and Technology: Waqas Haque and Shaalan Beg

Oncology Data Advisor®

Related tracks